Methods of identifying HIV patients sensitive to therapy with GP120 V3 glycan-directed antibodies

A method of reducing the HIV-1 viral load in a human subject in need thereof, the method comprising:

• a) Identifying a human subject who is infected with HIV-1 clade B;
• b) Identifying in a biological sample from the subject via polynucleotide or polypeptide sequencing an HIV-1 gp120 comprising the following amino acid residues:
• N332glycan, D325, and one or more amino acid residues selected from the group consisting of T63, L179, T320, and H330, wherein the amino acid positions are with reference to SEQ ID NO:
• 4, wherein the biological sample is selected from blood, peripheral blood mononuclear cells (PBMCs), serum, plasma, semen or lymph nodes;
• and
• c) Administering to the subject an effective amount of an antibody or antigen-binding fragment thereof that comprises a VH region comprising a VH-CDR1, a VH-CDR2, and a VH-CDR3;
• and a VL region comprising a VL-CDR1, a VL-CDR2, and a VL-CDR3, wherein the VH region and the VL region bind to an epitope of the HIV-1 gp120 within the third variable loop (V3);
• wherein the VH-CDR1, the VH-CDR2, the VH-CDR3 the VL-CDR1, the VL-CDR2, and the VH-CDR3 comprise the sequences set forth, respectively, in:
• i. SEQ ID NOs.:
• 7, 8, 9, 10, 11 and 12;
• ii. SEQ ID NOs.:
• 7, 13, 9, 10, 11 and 12;
• iii. SEQ ID NOs.:
• 14, 15, 16, 17, 11 and 18;
• iv. SEQ ID NOs.:
• 14, 19, 20, 17, 11 and 18;
• V. SEQ ID NOs.:
• 21, 22, 23, 24, 25 and 26;
• vi. SEQ ID NOs.:
• 21, 22, 27, 24, 25 and 26;
• vii. SEQ ID NOs.:
• 28, 29, 30, 31, 32 and 33;
• or
• viii. SEQ ID NOs.:
• 34, 35, 36, 37, 25 and 38.